Select Publications
Click title to access publication
Pridopidine does not significantly prolong the QTc interval at the clinically relevant therapeutic dose
Darpo B, Geva M, Ferber G, et al. Neurol Ther. 2023;12(2)597-617. doi:10.1007/s40120-023-00449-w
Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine
Wang SM, Wu HE, Yasui Y, et al. Autophagy. 2023;19(1):126-151. doi:10.1080/15548627.2022.2063003
Pridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model
Lenoir S, Lahaye RA, Vitet H, et al. Neurobiol Dis. 2022;173:10585. doi:10.1016/j.nbd.2022.105857
Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma
Geva M, Gershoni-Emek N, Naia L, et al. Sci Rep. 2021;11(1):21975. doi:10.1038/s41598-021-01077-w
Pridopidine reduces mutant huntingtin-induced endoplasmic reticulum stress by modulation of the sigma-1 receptor
Shenkman M, Geva M, Gershoni-Emek N, et al. J Neurochem. 2021;158(2):467-481. doi:10.1111/jnc.1536
Sigma-1 receptor (S1R) interaction with cholesterol: mechanisms of S1R activation and its role in neurodegenerative diseases
Zhemkov V, Geva M, Hayden MR, Bezprozvanny I. Int J Mol Sci. 2021;22(8):4082. doi:10.3390/ijms22084082
The sigma-1 receptor mediates pridopidine rescue of mitochondrial function in Huntington disease models
Naia L, Ly P, Mota SI, et al. Neurotherapeutics. 2021;18(2):1017-1038. doi:10.1007/s13311-021-01022-9
Effects of pridopidine on functional capacity in early-stage participants from the PRIDE-HD study
McGarry A, Leinonen M, Kieburtz K, Geva M, Olanow CW, Hayden M. J Huntingtons Dis. 2020;9(4):371-380. doi:10.3233/JHD-200440
Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study
Grachev ID, Meyer PM, Becker GA, et al. Eur J Nucl Med Mol Imaging. 2021;48(4):1103-1115. doi:10.1007/s00259-020-05030-3
Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington disease
McGarry A, Auinger P, Kieburtz K, et al. J Huntingtons Dis. 2020;9(2):173-184. doi:10.3233/JHD-190393
Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor
Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA. Neurobiol Dis. 2019;129:118-129. doi:10.1016/j.nbd.2019.05.009
Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques
Johnston TH, Geva M, Steiner L, et al. Mov Disord. 2019;34(5):708-716. doi:10.1002/mds.27565
Impairment and restoration of homeostatic plasticity in cultured cortical neurons from a mouse model of Huntington disease
Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA. Front Cell Neurosci. 2019;13:209. doi:10.3389/fncel.2019.00209
Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model
Ionescu A, Gradus T, Altman T, et al. Cell Death Dis. 2019;10(3):210. doi:10.1038/s41419-019-1451-2
Pridopidine induces functional neurorestoration via the sigma-1 receptor in a mouse model of Parkinson’s disease
Francardo V, Geva M, Bez F, et al. Neurotherapeutics. 2019;16(2):465-479. doi:10.1007/s13311-018-00699-9
Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
Reilmann R, McGarry A, Grachev ID, et al; European Huntington’s Disease Network; Huntington Study Group investigators.. Lancet Neurol. 2019;18(2):165-176. doi:10.1016/S1474-4422(18)30391-0
Pridopidine stabilizes mushroom spines in mouse models of Alzheimer’s disease by acting on the sigma-1 receptor
Ryskamp D, Wu L, Wu J, et al. Neurobiol Dis. 2019;124:489-504. doi:10.1016/j.nbd.2018.12.022
Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
Kusko R, Dreymann J, Ross J, et al. Mol Neurodegener. 2018;13(1):25. doi:10.1186/s13024-018-0259-3
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice
Garcia-Miralles M, Geva M, Tan JY, et al. JCI Insight. 2017;2(23):e95665. doi:10.1172/jci.insight.95665
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease
Ryskamp D, Wu J, Geva M, et al. Neurobiol Dis. 2017;97(pt A):46-59. doi:10.1016/j.nbd.2016.10.006
Pridopidine activates neuroprotective pathways impaired in Huntington Disease
Geva M, Kusko R, Soares H, et al. Hum Mol Genet. 2016;25(18):3975-3987. doi:10.1093/hmg/ddw2
Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
Garcia J, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker R, Saft C, Magnet M, Sword A, Rembratt A, Tedroff J, MermaiHD study investigators. Lancet Neurology. 2011; Dec;10(12):1049-57. doi: 10.1016/S1474-4422(11)70233-2